Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 30:35:100689.
doi: 10.1016/j.nmni.2020.100689. eCollection 2020 May.

Consideration of dornase alfa for the treatment of severe COVID-19 acute respiratory distress syndrome

A P Earhart  1 , Z M Holliday  2 , H V Hofmann  2 , A G Schrum  3   4   5
Affiliations

Consideration of dornase alfa for the treatment of severe COVID-19 acute respiratory distress syndrome

A P Earhart et al. New Microbes New Infect. .

Abstract

We propose a likely contribution to severe COVID-19 morbidity by extracellular DNA in neutrophil extracellular traps (NETs). Dornase alfa degrades extracellular DNA to reduce mucus rigidity and accumulation, and was associated with respiratory improvement in a first patient. Dornase alfa should be considered for clinical trials in treatment of severe COVID-19.

Keywords: COVID-19; DNAse 1; Neutrophil extracellular trap; acute respiratory distress syndrome; dornase alfa.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Model of how dornase alfa-sensitive neutrophil extracellular traps (NETs) from neutrophils may reinforce mucus accumulation, rigidity and airway occlusion in severe coronavirus disease 2019 (COVID-19). (a) Viral infection causes inflammation and respiratory distress (darkened lungs). Lung-infiltrating neutrophils produce NETs whose large quantities of chromosomal, extracellular DNA are susceptible to degradation by dornase alfa (recombinant human deoxyribonuclease I, right). (b) Close up view of alveoli. Without dornase alfa treatment (left), NETs reinforce the accumulation and rigidity of mucus that can increase lung injury and reduce oxygenation. Dornase alfa treatment (right) reduces NET-mediated reinforcement of mucus, making it less rigid (lighter yellow) and facilitating mucus clearance, so reducing lung injury and increasing gas exchange. (c) The rate at which recovery from severe COVID-19 occurs naturally (left, thin arrow) might be increased by dornase alfa treatment (right, thicker arrow). Figure was created with BioRender.
See this image and copyright information in PMC

References

    1. Yang C., Montgomery M. Dornase α for cystic fibrosis. Cochrane Database Syst Rev. 2018;9:CD001127. - PMC - PubMed
    1. Morris C., Mullan B. Use of dornase α in the management of ARDS. Anaesthesia. 2004;59:1249. - PubMed
    1. Riethmueller J., Borth-Bruhns T., Kumpf M., Vonthein R., Wiskirchen J., Stern M. Recombinant human deoxyribonuclease shortens ventilation time in young, mechanically ventilated children. Pediatr Pulmonol. 2006;41:61–66. - PubMed
    1. Pottecher J., Noll E., Borel M., Audibert G., Gette S., Meyer C. Protocol for TRAUMADORNASE: a prospective, randomized, multicentre, double-blinded, placebo-controlled clinical trial of aerosolized dornase α to reduce the incidence of moderate-to-severe hypoxaemia in ventilated trauma patients. Trials. 2020;21:274. - PMC - PubMed
    1. Cheng O.Z., Palaniyar N. NET balancing: a problem in inflammatory lung diseases. Front Immunol. 2013;4:1. - PMC - PubMed